Top-News
Biotechnologie Großbritannien

Autolus Therapeutics plc Aktie

Aktie
WKN:  A2JNZJ ISIN:  US05280R1005 US-Symbol:  AUTL
1,40 $
+0,05 $
+3,70%
1,2360 € 17:34:01 Uhr
Depot/Watchlist
Aktienanzahl *
266,09 Mio.
Marktkapitalisierung *
327,64 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 10.02.2025

Autolus Therapeutics plc News

08.02.24 - wallstreetONLINE Redaktion
Neue Kooperation: BioNTech kooperiert mit Autolus! Aktienkurs legt los
BioNTech hat in letzter Zeit kaum für Schlagzeilen gesorgt, weder bei den Unter­nehmens­nachrichten noch bei der Entwicklung des Aktienkurses. Doch heute haben die Mainzer ...
20.12.23 - PR Newswire
Thinking about buying stock in Beyond Air, bluebird bio, Riot Platforms, Autolus Therapeutics, or Forge Global Holdings?
Thinking about buying stock in Beyond Air, bluebird bio, Riot Platforms, Autolus Therapeutics, or Forge Global Holdings? PR Newswire
28.11.23 - PR Newswire
Thinking about buying stock in Ardelyx, Autolus Therapeutics, SMX (Security Matters) PLC, Hudson Pacific Properties, or Dharma Polimetal?
Thinking about buying stock in Ardelyx, Autolus Therapeutics, SMX (Security Matters) PLC, Hudson Pacific Properties, or Dharma Polimetal? PR Newswire
22.11.23 - PR Newswire
Thinking about trading options or stock in Medtronic, Applied Materials, Autolus Therapeutics, Bright Minds Biosciences, or Tremor International?
Thinking about trading options or stock in Medtronic, Applied Materials, Autolus Therapeutics, Bright Minds Biosciences, or Tremor International? PR Newswire
12.10.22 - PR Newswire
Thinking about buying stock in Autolus Therapeutics, Uber, Galectin Therapeutics, El Pollo LoCo, or BioNano Genomics?
Thinking about buying stock in Autolus Therapeutics, Uber, Galectin Therapeutics, El Pollo LoCo, or BioNano Genomics? PR Newswire
05.10.22 - PR Newswire
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing PR Newswire
05.10.22 - PR Newswire
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing PR Newswire
08.11.21 - PR Newswire
Thinking about buying stock in Pioneer Power Solutions, Lucid Group, TAL Education, Meten Holding, or Autolus Therapeutics?
Thinking about buying stock in Pioneer Power Solutions, Lucid Group, TAL Education, Meten Holding, or Autolus Therapeutics? PR Newswire
02.08.21 - PR Newswire
Thinking about buying stock in Infinity Pharmaceuticals, Autolus Therapeutics, Affirm Holdings, Erytech Pharma, or Exela Technologies?
Thinking about buying stock in Infinity Pharmaceuticals, Autolus Therapeutics, Affirm Holdings, Erytech Pharma, or Exela Technologies? PR Newswire
01.04.19 - PR Newswire
Arix Bioscience plc - Autolus Presents Initial AUTO1 Data at AACR
Arix Bioscience plc - Autolus Presents Initial AUTO1 Data at AACR PR Newswire
01.04.19 - PR Newswire
Arix Bioscience plc - Autolus Presents Initial AUTO1 Data at AACR
Arix Bioscience plc - Autolus Presents Initial AUTO1 Data at AACR PR Newswire
29.03.19 - PR Newswire
Arix Bioscience plc - Autolus Announces Conference Call to Discuss AUTO1 ALLCAR19 Data Presentation at the AACR Annual Meeting 2019
Arix Bioscience plc - Autolus Announces Conference Call to Discuss AUTO1 ALLCAR19 Data Presentation at the AACR Annual Meeting 2019 PR Newswire
29.03.19 - PR Newswire
Arix Bioscience plc - Autolus Announces Conference Call to Discuss AUTO1 ALLCAR19 Data Presentation at the AACR Annual Meeting 2019
Arix Bioscience plc - Autolus Announces Conference Call to Discuss AUTO1 ALLCAR19 Data Presentation at the AACR Annual Meeting 2019 PR Newswire
25.02.19 - PR Newswire
Autolus Therapeutics Reports Financial and Operational Results for the Transition Period from October 1 to December 31, 2018
Autolus Therapeutics Reports Financial and Operational Results for the Transition Period from October 1 to December 31, 2018 - Conference Call to be held on February 25, 2019 ...
21.02.19 - PR Newswire
Autolus Therapeutics to Announce Financial Results for the Transition Period from October 1, 2018 to December 31, 2018 and Host Conference Call on February 25, 2019
Autolus Therapeutics to Announce Financial Results for the Transition Period from October 1, 2018 to December 31, 2018 and Host Conference Call on February 25, 2019 PR ...
19.02.19 - PR Newswire
Arix Bioscience plc: Autolus Announces Updated Results From CARPALL Trial
Arix Bioscience plc: Autolus Announces Updated Results From CARPALL Trial PR Newswire
19.02.19 - PR Newswire
Arix Bioscience plc: Autolus Announces Updated Results From CARPALL Trial
Arix Bioscience plc: Autolus Announces Updated Results From CARPALL Trial PR Newswire
19.02.19 - PR Newswire
Autolus Therapeutics Announces Updated Results from Ongoing CARPALL Trial of Pediatric Acute Lymphoblastic Leukemia Presented at the EHA 1st European CAR T Cell Meeting in Paris
Autolus Therapeutics Announces Updated Results from Ongoing CARPALL Trial of Pediatric Acute Lymphoblastic Leukemia Presented at the EHA 1st European CAR T Cell Meeting ...
03.12.18 - PR Newswire
Arix Bioscience plc: Autolus Announces Update on AUTO4 and AUTO5 Programmes
Arix Bioscience plc: Autolus Announces Update on AUTO4 and AUTO5 Programmes PR Newswire
03.12.18 - PR Newswire
Arix Bioscience plc: Autolus Announces Update on AUTO4 and AUTO5 Programmes
Arix Bioscience plc: Autolus Announces Update on AUTO4 and AUTO5 Programmes PR Newswire

Newssuche

Videos

newspaper
30.04.25 +13,48%
Technical Trading: Cotton Long Chance
Cotton Long Typ: Turbo Open End WKN: VP6N8D Hebel: 3,80 Laufzeit: OpenEnd Einstieg: Market ... Mehr »